HL GENOMICS Co., Ltd.: what insiders have been doing
Insider filings for HL GENOMICS Co., Ltd. are scarce in the DART (FSS) feed. This page will fill in as new trades are disclosed. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.
Insider Decl.
n/a
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 564 of 26,911 companies
84.0
score / 100
Value86
Quality82
FCF yld7.6%
Earn yld17%
EV/EBITDA4.8x
ROE·
Gross mgn43%
Net mgn29%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
₩7,480
Analyst consensus
Income statement
Revenue₩28.9B
Gross profit₩12.5B43% margin
EBITDA₩10.7B37% margin
Net income₩8.5B29.3% margin
Balance sheet & cash
Market cap₩58.2B
Total debt₩1.8B
Free Cash Flow₩3.8B
Profitability & ownership
% insiders66.1%
% institutions0.0%
Declarations2 total
- Other0DART
- Other0DART
2 of 2 declarations
About HL GENOMICS Co., Ltd.
H.L. Genomics is a company listed on the XKRX market, specializing in the field of genomics. It focuses on developing innovative solutions for genetic research and diagnostics.